Celltrion's Zymfentra gets 90% distribution channel in US
South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...
Kobiolabs gets US patent for oral obesity drug candidate
Kobiolabs Co., a South Korean microbiome-based new drug development company, announced on Wednesday that it has a patent for Roseburia intestinalis ...
Inventage Lab, Yuhan to co-work for obesity treatment
South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting inj...
LG Chem out-licenses obesity drug candidate to US firm
LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...
Cosmax targets Thailand with K-beauty cosmetic formulations
Cosmax Inc., South Korea's largest cosmetics manufacturer that specializes in original design manufacturing (ODM), announced on Monday that it is ac...
HLB gets global rights to Chinese liver cancer drug
South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...
AriBio to sell dementia drug AR1001 in China with partner
South Korea's clinical-stage biotech company AriBio Co. on Wednesday said it signed a memorandum of understanding on strategic cooperation with Chin...
AriBio applies for Phase 3 clinical trials in China for oral dementia drug
South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...
Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA
Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean ph...
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Daewoong, Onchorus to undertake research on mRNA anticancer drugs
Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...
S.Korea's Alteogen signs $145 million tech export deal with Swiss company
South Korea's bio company Alteogen Inc. on Friday said it signed its fourth technology export contract since its 2018 development of the human recom...
S.Korea's Medicox boosts unit for oral insulin, medical cannabis
South Korea's Medicox Co. on Wednesday said it will raise 40 billion won ($32 million) to boost its unit for oral insulin and cannabidiol (CBD).The ...
Helixmith acquires US patent on new freeze-dried formulation
South Korea's biotech company Helixmith Co. said Wednesday it has developed and patented a new freeze-dried formulation for Engensis (VM202), a non-...
Korean bio firms look to pills, patches for people who fear needles
Getting shots of a drug or vaccine over a long period is not easy for many people.That's probably why global biopharmaceutical companies and biotech...
